KR102252009B1 - Antiviral or antibacterial composition containing extracts of Torreya nucifera leaf - Google Patents
Antiviral or antibacterial composition containing extracts of Torreya nucifera leaf Download PDFInfo
- Publication number
- KR102252009B1 KR102252009B1 KR1020200105977A KR20200105977A KR102252009B1 KR 102252009 B1 KR102252009 B1 KR 102252009B1 KR 1020200105977 A KR1020200105977 A KR 1020200105977A KR 20200105977 A KR20200105977 A KR 20200105977A KR 102252009 B1 KR102252009 B1 KR 102252009B1
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- antiviral
- present
- extract
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 54
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title abstract description 45
- 230000000844 anti-bacterial effect Effects 0.000 title abstract description 15
- 244000111306 Torreya nucifera Species 0.000 title description 4
- 235000006732 Torreya nucifera Nutrition 0.000 title description 4
- 235000018185 Betula X alpestris Nutrition 0.000 claims abstract description 30
- 235000018212 Betula X uliginosa Nutrition 0.000 claims abstract description 30
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000005487 catechin Nutrition 0.000 claims abstract description 13
- 229950001002 cianidanol Drugs 0.000 claims abstract description 12
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000001263 FEMA 3042 Substances 0.000 claims abstract description 10
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims abstract description 10
- 235000015523 tannic acid Nutrition 0.000 claims abstract description 10
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims abstract description 10
- 229940033123 tannic acid Drugs 0.000 claims abstract description 10
- 229920002258 tannic acid Polymers 0.000 claims abstract description 10
- 241000700605 Viruses Species 0.000 claims description 27
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims description 7
- 206010022000 influenza Diseases 0.000 claims description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 3
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 3
- 208000004232 Enteritis Diseases 0.000 claims description 3
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 3
- KBPUBCVJHFXPOC-UHFFFAOYSA-N ethyl 3,4-dihydroxybenzoate Chemical compound CCOC(=O)C1=CC=C(O)C(O)=C1 KBPUBCVJHFXPOC-UHFFFAOYSA-N 0.000 claims description 3
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 3
- 229940114124 ferulic acid Drugs 0.000 claims description 3
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 3
- 235000001785 ferulic acid Nutrition 0.000 claims description 3
- 235000004515 gallic acid Nutrition 0.000 claims description 3
- 229940074391 gallic acid Drugs 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 3
- 235000005493 rutin Nutrition 0.000 claims description 3
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 3
- 229960004555 rutoside Drugs 0.000 claims description 3
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 3
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 claims description 2
- PFTAWBLQPZVEMU-UHFFFAOYSA-N catechin Chemical compound OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UHFFFAOYSA-N 0.000 claims description 2
- 229940117954 naringenin Drugs 0.000 claims description 2
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 claims description 2
- 235000007625 naringenin Nutrition 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 abstract description 42
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- 238000004659 sterilization and disinfection Methods 0.000 description 26
- 241000894006 Bacteria Species 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- 235000019441 ethanol Nutrition 0.000 description 13
- 241000607768 Shigella Species 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 8
- 239000000645 desinfectant Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 230000000845 anti-microbial effect Effects 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 6
- 241000607762 Shigella flexneri Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 5
- 241000725643 Respiratory syncytial virus Species 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 241001137860 Rotavirus A Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000711920 Human orthopneumovirus Species 0.000 description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000005727 virus proliferation Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010016952 Food poisoning Diseases 0.000 description 2
- 208000019331 Foodborne disease Diseases 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- PDHAOJSHSJQANO-OWOJBTEDSA-N Oxyresveratrol Chemical compound OC1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 PDHAOJSHSJQANO-OWOJBTEDSA-N 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000012812 general test Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 201000010740 swine influenza Diseases 0.000 description 2
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- YWJXCIXBAKGUKZ-HJJNZUOJSA-N Bergenin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]2C3=C(O)C(OC)=C(O)C=C3C(=O)O[C@@H]21 YWJXCIXBAKGUKZ-HJJNZUOJSA-N 0.000 description 1
- XULPLJSODQQHPH-UHFFFAOYSA-N Bergenin Natural products OCC1OC2C(OC(=O)c3cc(O)c(CO)c(O)c23)C(O)C1O XULPLJSODQQHPH-UHFFFAOYSA-N 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241001660259 Cereus <cactus> Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 241000723267 Diospyros Species 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 241000751185 Listeria monocytogenes ATCC 19115 Species 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241001116495 Taxaceae Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000488908 Torreya Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000016674 enamel mineralization Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/06—Coniferophyta [gymnosperms], e.g. cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Alternative & Traditional Medicine (AREA)
- Virology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 카테킨 성분과 탄닌산 성분을 풍부하게 포함하는 비자나무 잎 추출물을 포함하는 항바이러스용 조성물 및 인체에 무해하며 항균 활성이 뛰어난 비자나무 잎 추출물을 포함하는 살균용 조성물에 관한 것이다.The present invention relates to an antiviral composition comprising a catechin component and a tannic acid component richly containing a birch leaf extract, and a sterilizing composition comprising a birch leaf extract that is harmless to the human body and has excellent antibacterial activity.
Description
본 발명은 카테킨 성분과 탄닌산 성분을 풍부하게 포함하는 비자나무 잎 추출물을 포함하는 항바이러스용 조성물 및 인체에 무해하며 항균 활성이 뛰어난 비자나무 잎 추출물을 포함하는 살균용 조성물에 관한 것이다. The present invention relates to an antiviral composition comprising a catechin component and a tannic acid component richly containing a birch leaf extract, and a sterilizing composition comprising a birch leaf extract that is harmless to the human body and has excellent antibacterial activity.
매년 주기적으로 반복 유행하는 식중독, 폐렴 등 세균성 감염병 및 신종 플루, 조류 인플루엔자 및 코로나 바이러스 등 다양한 바이러스성 감염병이 사회적으로 큰 문제를 일으켜, 세균 및 바이러스 질병의 효과적인 대책에 대해 사회적으로 큰 관심을 불러일으키고 있다.Bacterial infectious diseases such as food poisoning, pneumonia, and various viral infectious diseases such as swine flu, avian influenza, and coronavirus, which are recurring every year, cause major social problems, arousing great social interest in effective countermeasures against bacterial and viral diseases. have.
병원성 세균(Pathogenic bacteria)은 질병을 일으키는 세균으로, 결핵을 일으키는 결핵균, 폐렴을 일으킬 수 있는 연쇄상구균이나 슈도모나스, 식중독을 일으킬 수 있는 이질균, 캄필로박터, 살모넬라 등이 대표적인 병원성 세균으로 감염된 숙주 세포에 직접적, 간접적 손상을 일으킨다. 세균 감염은 일반적으로 항생제로 치료할 수 있는데, 항생제는 세균을 죽이면 살균제로, 성장을 억제하면 정균작용제로 분류한다. 하지만 항생제의 지속적인 사용에는 내성이 발생할 수 있어 여러 항생제에 대해 동시 내성을 갖는 다제내성균주(multidrug resistant bacteria)의 출현으로 인한 문제점이 대두되고 있었다. Pathogenic bacteria are causing diseases , and host pathogenic bacteria infected with host cells infected with tuberculosis bacteria that cause tuberculosis and pneumonia are streptococcus or Pseudomonas that can cause food poisoning, campylobacter, Salmonella, etc. It causes direct or indirect damage. Bacterial infections can generally be treated with antibiotics, and antibiotics are classified as disinfectants if they kill bacteria and bacteriostatic agents if they inhibit growth. However, the continued use of antibiotics can result in resistance, and a problem has been raised due to the emergence of multidrug resistant bacteria that have simultaneous resistance to several antibiotics.
바이러스(virus)는 세균여과지(0.22㎛)를 통과하는 크기의 미세 감염형 병원성 입자이다. 바이러스는 숙주세포의 종류에 따라 박테리오파지, 식물 바이러스, 동물 바이러스로 분류하기도 하며, 핵산의 종류에 따라 DNA 바이러스, RNA 바이러스 등으로 분류한다. 현재 바이러스성 질병을 예방하기 위한 가장 좋은 방법은 백신접종이지만, 백신의 역가, 안전 및 안정성의 문제점을 보완해 줄 수 있는 바이러스 예방용 억제제의 개발 및 보급에 대한 관심이 날로 높아지고 있다. Viruses are microscopic infectious pathogenic particles having a size that passes through a bacterial filter paper (0.22 μm). Viruses are classified into bacteriophage, plant virus, and animal virus according to the type of host cell, and are classified into DNA virus, RNA virus, etc. according to the type of nucleic acid. Currently, vaccination is the best way to prevent viral diseases, but interest in the development and distribution of inhibitors for virus prevention that can complement the problems of the potency, safety and stability of the vaccine is increasing day by day.
세균성 또는 바이러스성 전염병 및 감염병 확산의 방지를 위해 손 세척의 중요성에 대한 인지도가 높아지고 있는 실정이다. 손 세척을 위해 사용되는 손 소독제는 손 세정제 또는 핸드 새니타이저(hand sanitizer)라고도 하며, 물로 손을 씻는 것을 대신하거나, 손 소독제 사용 후 물로 손을 씻는 항균, 항미생물용 물질이다. 화학물질로 구성된 액체형 소독제나 젤 형태 소독제로 주로 분사형이나 펌핑형태로 사용한다. 이러한 손 소독제의 주요 성분은 에탄올 등으로 이루어져 있으나, 손 소독제 내의 에탄올의 함량에 따라 살균력이 떨어지는 한계점이 존재하며, 이를 보완하기 위해 살균력을 보강하기 위한 추가 화학 물질을 첨가할 수 있다. 그러나, 소비자의 건강 지향적 요구가 증대하여 화학물질의 기피현상이 사회전반에서 일어나고 있고, 특히 피부 등에 적용하는 화장품 같은 경우에는 소비자들이 전 성분을 확인하여 구입, 사용하기도 하는 등의 현상을 고려할 때, 추가적인 화학물질을 첨가하는 대신에 천연소재로부터 얻은 항균성 물질을 이용하여 살균력을 향상 시키려는 기술 개발이 요구되고 있다. There is a growing awareness of the importance of hand washing to prevent the spread of bacterial or viral infectious diseases and infectious diseases. Hand sanitizers used for hand washing, also known as hand sanitizers or hand sanitizers, are antimicrobial and antimicrobial substances that replace hand washing with water or wash hands with water after using hand sanitizers. It is a liquid type disinfectant or gel type disinfectant composed of chemical substances, and is mainly used in the form of spraying or pumping. The main component of such a hand sanitizer is composed of ethanol, but there is a limitation in that the sterilization power is lowered depending on the content of ethanol in the hand sanitizer, and additional chemical substances to reinforce the sterilization power may be added to compensate for this. However, as consumers' health-oriented demands are increasing, the avoidance of chemical substances is occurring in society. Especially, in the case of cosmetics that are applied to skin, etc., when considering the phenomenon of consumers checking all ingredients and purchasing and using them, Instead of adding additional chemicals, there is a need for technology development to improve sterilization by using antimicrobial substances obtained from natural materials.
비자나무(학명: Torreya nucifera, 영문명: Nut-bearing torreya, Japanese torreya)는 우리나라의 남부지방과 일본에 자생하는 주목과의 상록교목으로 비자나무의 성숙된 종자에서 종피를 제거하고 건조한 것을 비자라 하며, 식욕증진, 소화촉진, 변비 및 치질 등의 약리작용을 나타내며 구충제로 이용되어 왔고, 공개특허공보 제10-2018-0006551호 등에는 비자나무 및 비자열매 열수추출물을 유효성분으로 포함하는 피부 개선용 항균 조성물이 보고되어 있으나, 여드름균 등 균주에 대한 항균 효과를 나타낼 뿐, 감염병 예방을 위한 균주를 살균하는 것에 대한 발명이 아니었으며, 종래 비자 추출물의 항바이러스 효과에 대해서는 거의 알려지지 않은 실정이었다. Bismuth tree (scientific name: Torreya nucifera, English name: Nut-bearing torreya, Japanese torreya) is an evergreen tree of the Yew family native to the southern regions of Korea and Japan. , Appetite promotion, digestion promotion, constipation and hemorrhoids, etc., and has been used as an anthelmintic. Although antimicrobial compositions have been reported, it only exhibits antibacterial effects against strains such as acne bacteria, and it is not an invention for sterilizing strains for preventing infectious diseases, and little is known about the antiviral effect of conventional visa extracts.
본 발명의 목적은 카테킨 성분과 탄닌산 성분을 풍부하게 포함하는 비자나무 잎 추출물을 사용하여 인체에 무해하며 항균활성이 뛰어난 비자나무 잎 추출물을 포함하는 소독제 조성물을 제공하는 것이다. It is an object of the present invention to provide a disinfectant composition comprising a birch leaf extract which is harmless to the human body and has excellent antibacterial activity by using a birch leaf extract rich in a catechin component and a tannic acid component.
상기 목적을 달성하기 위하여, 본 발명은 비자나무 잎 추출물과, 이를 포함하는 항바이러스용 조성물 또는 이를 포함하는 살균용 조성물을 제공한다.In order to achieve the above object, the present invention provides a birch leaf extract, an antiviral composition comprising the same, or a sterilizing composition comprising the same.
이하 본 발명을 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명자들은 천연 소재로부터 얻은 항바이러스성 및 항균성 물질을 찾던 중, 비자나무 잎 추출물의 항바이러스성 및 항균 효과가 뛰어나고, 피부에 직접 사용시에도 독성이나 부작용 등이 전혀 없음을 발견하여 본 발명을 완성하게 되었다.While searching for antiviral and antimicrobial substances obtained from natural materials, the present inventors completed the present invention by discovering that the extract of birch leaves has excellent antiviral and antibacterial effects, and has no toxicity or side effects even when used directly on the skin. Was done.
본 명세서에서, ‘비자나무 잎 추출물’은 비자나무(Torreya nucifera) 의 다양한 기관, 예컨대 과실, 잎, 꽃, 줄기 및 뿌리 중 비자나무 잎으로부터 추출하여 얻은 것이다.In the present specification, the'Visa leaf extract' is obtained by extracting from the leaves of the Visaceae tree among various organs of Torreya nucifera, such as fruits, leaves, flowers, stems, and roots.
본 발명의 일 구현예에서, 비자나무 잎 추출물은 물 또는 유기 용매로 추출하여 얻은 유지 성분을 포함한다. 상기에서 유기 용매는 탄소수 1 내지 4의 알코올, 헥산, 아세톤, 에틸아세테이트, 디에틸에테르, 에틸메틸케톤 및 클로로포름으로 이루어진 군에서 선택된 하나 이상을 포함하나, 이에 제한되는 것은 아니다. 상기 유기 용매는 바람직하게는 에탄올일 수 있다.In one embodiment of the present invention, the extract of birch leaves includes a fat or oil component obtained by extraction with water or an organic solvent. In the above, the organic solvent includes at least one selected from the group consisting of alcohol having 1 to 4 carbon atoms, hexane, acetone, ethyl acetate, diethyl ether, ethyl methyl ketone, and chloroform, but is not limited thereto. The organic solvent may preferably be ethanol.
본 발명의 일 구현예에 있어서, 상기 에탄올의 농도는 70%(v/v) 내지 100%(무수에탄올)일 수 있다. 상기 유기 용매의 농도가 70%(v/v) 미만인 경우 추출물 단위 중량 대비 지용성 성분의 추출량이 감소한다.In one embodiment of the present invention, the concentration of ethanol may be 70% (v/v) to 100% (anhydrous ethanol). When the concentration of the organic solvent is less than 70% (v/v), the extraction amount of the fat-soluble component is reduced relative to the unit weight of the extract.
본 발명의 일 구현예에 있어서, 상기 비자나무 잎 10 내지 30 중량%와 상기 용매를 70 내지 90 중량%로 혼합하여 추출한 것을 특징으로 한다. In one embodiment of the present invention, it is characterized in that the extract is extracted by mixing 10 to 30% by weight of the birch leaf and 70 to 90% by weight of the solvent.
본 발명의 일 구현예에 있어서, 상기 비자나무 잎 추출 조건은 온도 60 ~ 80 ℃에서 0시간 초과 4시간 이하, 가압하에 추출한 것을 특징으로 한다. In one embodiment of the present invention, the extracting conditions for the leaves of the birch tree are characterized in that the extraction is performed under pressure, exceeding 0 hours and 4 hours or less at a temperature of 60 to 80°C.
추출 온도가 60℃ 미만인 경우 목표하는 추출 정도를 달성하기 어렵고, 추출 온도가 80℃ 초과 또는 추출 시간이 4시간 초과인 경우 식물 정유의 휘발성 성분이 지나치게 휘발될 가능성이 있어 생산성이 감소할 우려가 있다. 추출 시 휘발성 성분의 휘발을 방지하기 위해 가압하에 추출한다.If the extraction temperature is less than 60℃, it is difficult to achieve the target level of extraction, and if the extraction temperature exceeds 80℃ or the extraction time is more than 4 hours, there is a possibility that the volatile components of plant essential oils may be excessively volatilized, resulting in a decrease in productivity. . During extraction, it is extracted under pressure to prevent volatilization of volatile components.
본 발명의 일 구현예에 있어서, 상기 비자나무 잎 추출물은 프로토카테츄산 에틸 에스테르, 4-히드록시 벤조산, 시링산, 쿠마르산, 루틴, 페룰산, 나린제닌, 레스베라톨, 니코틴산, 갈릭산, 프로토카테츄산, 카테킨, 탄닌산 중 선택되는 하나 이상을 포함하는 것을 특징으로 하는 비자나무 잎 추출물을 포함하는 살균용 조성물을 제공한다.In one embodiment of the present invention, the extract of birch leaves is protocatechuic acid ethyl ester, 4-hydroxy benzoic acid, sirinic acid, coumaric acid, rutin, ferulic acid, naringenin, resveratol, nicotinic acid, gallic acid, Protocatechuic acid, catechin, it provides a sterilizing composition comprising a leaf extract of the birch, characterized in that it comprises at least one selected from tannic acid.
카테킨은 폴리페놀의 일종으로 녹차나 카카오 열매 등에 다량 함유되어 있다. 카테킨은 발암억제, 동맥경화, 혈압상승 억제, 혈전예방, 항비만, 항당뇨, 항균, 해독작용, 소염작용, 충치예방, 구갈방지, 장내 세균총 정상화 등 다양한 효과가 있는 것으로 알려져 있다. Catechin is a type of polyphenol and is contained in large amounts in green tea and cacao. Catechins are known to have various effects such as cancer inhibition, arteriosclerosis, blood pressure increase inhibition, blood clot prevention, anti-obesity, anti-diabetes, antibacterial, detoxification, anti-inflammatory action, tooth decay prevention, mouth mouth prevention, and normalization of the intestinal flora.
탄닌산은 타닌(tannin), 탄닌이라고도 하며, 아주 떫은 맛을 내는 폴리페놀의 일종으로써 식물에 의해 합성되며 주로 과일류, 감, 도토리, 차 등에 많이 함유돼 있다. 혈관의 탄력을 높이는 역할을 하기도 하고 치아의 에나멜 형성을 도와 충치 예방 효과, 항균 효과를 나타내는 것으로 알려져 있다.Tannic acid is also called tannin and tannin, and is a kind of polyphenol that gives off a very astringent taste. It is synthesized by plants and is mainly contained in fruits, persimmons, acorns, and tea. It is known to increase the elasticity of blood vessels and to help the enamel formation of teeth to prevent tooth decay and to have antibacterial effects.
본 발명은 이러한 카테킨 함량을 10000ng/ml~30000ng/ml 및 탄닌산 함량 50000ng/ml~100000ng/ml 인 비자나무 잎 추출물을 포함할 수 있으며 종래 에탄올만으로는 살균력이 떨어지는 기술적 한계를 보완하고, 항바이러스성을 추가로 나타내는 효과적인 소독용 조성물을 제공한다. The present invention may include such a catechin content of 10000ng / ml ~ 30000ng / ml and tannic acid content of 50000ng / ml ~ 100000ng / ml of the extract of the birch leaves, and the conventional ethanol alone complements the technical limitations of poor sterilization, and has antiviral properties. It provides an effective disinfecting composition further shown.
본 발명의 일 구현예에 있어서, 상기 비자나무 잎 추출물을 포함하는 항바이러스용 조성물을 제공한다.In one embodiment of the present invention, it provides an antiviral composition comprising the extract of leaves of the birch tree.
본 발명의 일 구현예에 있어서, 상기 항바이러스용 조성물은 항바이러스용 화장료 조성물 또는 항바이러스용 약학적 조성물일 수 있다. In one embodiment of the present invention, the antiviral composition may be an antiviral cosmetic composition or an antiviral pharmaceutical composition.
본 발명의 일 구현예에 있어서, 상기 항바이러스용 조성물의 대상 바이러스는 호흡기세포융합 바이러스(Human respiratory syncytical virus), 장염바이러스 A(Rotavirus A), 인간 인플루엔자 A(Human influenza A, H1N1)로 이루어진 군에서 하나 이상에서 선택될 수 있다. In one embodiment of the present invention, the target virus of the antiviral composition is a group consisting of a human respiratory syncytical virus, an enteritis virus A, and a human influenza A (H1N1). Can be selected from one or more of.
상기 호흡기세포융합바이러스 (respiratory syncytial virus: RSV)는 호흡기 감염을 일으키는 바이러스이다. RSV는 Paramyxoviridae 과의 Pneumovirus 속에 속하며 바이러스 표면의 F 단백질이 근처 세포와 막 융합을 유도한다. 하부 호흡기 감염의 주된 원인이며 온대 지방의 겨울과 열대지방의 우기에 유행한다. RSV는 직경 120~200 nm의 지질 단백질이 포함된 외피를 가진 바이러스로 지질 단백질은 F (fusion), G (attachment), SH로 구성되어 있다. F와 G 단백질은 세포막과의 결합을 담당한다. RSV의 유전체는 약 15000 뉴클레오타이드로 단일 음성가닥 RNA이다.The respiratory syncytial virus (RSV) is a virus that causes respiratory infection. RSV belongs to the genus Pneumovirus of the family Paramyxoviridae , and the F protein on the viral surface induces membrane fusion with nearby cells. It is the main cause of lower respiratory tract infections and is prevalent in temperate winters and tropical rainy seasons. RSV is a virus with an envelope containing a lipoprotein of 120~200 nm in diameter, and the lipoprotein is composed of F (fusion), G (attachment), and SH. The F and G proteins are responsible for binding to the cell membrane. The genome of RSV is about 15000 nucleotides, which is a single negative-stranded RNA.
상기 로타바이러스(Rotavirus A)는 주로 유아와 소아 사이에서 설사를 유발하는 바이러스이다. reoviridae에 속하는 바이러스로 바이러스에 대한 면역은 각각의 감염 시마다 발생하여 이후의 감염은 증상이 덜 심각하다. 로타바이러스는 외피막을 갖고 있지 않고 3개의 단백질 층으로 구성된 정이십면체 캡시드가 11개의 dsRNA 유전체 분절을 싸고 있다. 제일 바깥쪽 층의 캡시드를 구성하는 단백질인 VP7과 VP4에 의해 바이러스의 혈청형이 결정되며, 두 단백질은 항체 생성을 유발하는 주요 항원이다.The rotavirus (Rotavirus A) is a virus that mainly causes diarrhea between infants and children. As a virus belonging to the reoviridae, immunity to the virus occurs with each infection, and subsequent infections have less severe symptoms. Rotavirus does not have an envelope and has an icosahedral capsid consisting of three protein layers, enclosing 11 dsRNA genome segments. Virus serotypes are determined by the proteins constituting the outermost layer of the capsid, VP7 and VP4, and both proteins are the main antigens that induce antibody production.
상기 인간 인플루엔자 A(Human influenza A)는 신종 인플루엔자 A(H1N1)라고도 지칭하며, A형 인플루엔자 바이러스가 변이를 일으켜 생긴 새로운 바이러스로, 2009년 전 세계적으로 유행하였다. 인간 인플루엔자 A는 막으로 둘러싸여 있는 외피보유바이러스이며, 외피막에는 특정 당단백질이 존재한다. 인플루엔자 바이러스 A는 바이러스의 표면 항원인 헤마글루티닌(hemagglutinin, HA)과 뉴라민분해효소 (neuraminidase, NA)의 종류에 따라 아형이 결정되며 H1N1, H3N2 등으로 표기한다. 외피막 내부에는 M1 기질 단백질 층이 존재하며, 기질 단백질 안쪽으로 유전물질이 뉴클레오캡시드 단백질과 결합된 형태로 존재한다. 유전물질은 단일가닥의 RNA이며, 하나가 아닌 7~8개의 절편으로 이루어져 있다.The human influenza A (H1N1) is also referred to as swine flu A (H1N1), and is a new virus caused by mutations of the type A influenza virus, and it became a worldwide epidemic in 2009. Human influenza A is an enveloped virus surrounded by a membrane, and a specific glycoprotein is present in the envelope. Influenza virus A is subtyped according to the types of hemagglutinin ( HA) and neuraminidase ( NA), which are the surface antigens of the virus, and are expressed as H1N1, H3N2, etc. The M1 matrix protein layer is present inside the envelope, and the genetic material is present in the form of binding to the nucleocapsid protein inside the matrix protein. The genetic material is a single-stranded RNA, and consists of 7 to 8 segments instead of one.
본 발명의 비자나무 잎 추출물은 바이러스의 외피막 여부와 무관하게, RNA 유전체 바이러스에 감염된 세포를 90~99.9%이상 사멸시키는 뛰어난 항바이러스 효과를 나타낸다. Regardless of whether the virus is enveloped or not, the extract of the leaves of the birch leaves of the present invention exhibits an excellent antiviral effect of killing more than 90 to 99.9% of cells infected with the RNA genome virus.
본 발명의 일 구현예에 있어서, 본 발명은 비자나무 잎 추출물을 10 내지 40 중량% 포함하는 것을 특징으로 하는 비자나무 잎 추출물을 포함하는 살균용 조성물을 제공한다. In one embodiment of the present invention, the present invention provides a sterilizing composition comprising a birch leaf extract, characterized in that it comprises 10 to 40% by weight of birch leaf extract.
상기 살균용 조성물은 에탄올을 30 내지 60 중량%, 정제수를 10 내지 30 중량%, 글리세린을 10 내지 20 중량%을 더 포함할 수 있다. The sterilizing composition may further include 30 to 60% by weight of ethanol, 10 to 30% by weight of purified water, and 10 to 20% by weight of glycerin.
상기 비자나무 잎 추출물이 10중량% 미만일 경우에는 조성물의 살균 효과가 감소하며, 40중량% 초과일 경우에는 피부 자극이 발생할 가능성이 있다. When the amount of the extract of the birch leaves is less than 10% by weight, the bactericidal effect of the composition decreases, and when it exceeds 40% by weight, skin irritation may occur.
상기 에탄올 함량이 30 중량% 미만일 경우에는 세균의 단백질 막을 녹이는 효과 등이 감소할 수 있으며, 60 중량% 초과인 경우에는 피부 자극이 발생할 가능성이 있다. When the ethanol content is less than 30% by weight, the effect of dissolving the protein membrane of bacteria may be reduced, and when it is more than 60% by weight, skin irritation may occur.
상기 정제수는 살균용 조성물의 농도를 조절하기 위하여 첨가하는 것이다. The purified water is added to adjust the concentration of the sterilizing composition.
상기 글리세린은 피부에 사용시 에탄올로 인해 발생하는 건조함을 해결하기 위한 보습인자로, 10중량% 미만 첨가할 경우 보습효과가 떨어져 사용 후 건조함을 느낄 수 있으며, 20중량% 초과 사용시에는 끈적한 제형으로 사용감을 나쁘게 할 수 있다.The glycerin is a moisturizing factor for solving the dryness caused by ethanol when used on the skin.If it is added less than 10% by weight, the moisturizing effect decreases and you may feel dry after use.If it is used in excess of 20% by weight, it becomes a sticky formulation. It can deteriorate the feeling of use.
본 발명의 일 구현예에 있어서, 상기 살균용 조성물은 살균용 화장료 조성물 또는 살균용 약학적 조성물인 것을 특징으로 한다.In one embodiment of the present invention, the sterilizing composition is characterized in that it is a sterilizing cosmetic composition or a sterilizing pharmaceutical composition.
본 발명의 일 구현예에 있어서, 상기 살균용 조성물의 대상 균주는 대장균(E.coli), 황색포도상구균(S.aureus), 녹농균(P.aeruginosa), 살모넬라균(S.typhimurium), 플렉스네리이질균 (S.flexneri), 폐렴간균(K.pneumoniae)으로 이루어진 군에서 선택되는 하나 이상인 것이 특징인 비자나무 잎 추출물을 포함하는 살균용 조성물을 제공한다. In one embodiment of the present invention, the target strain of the sterilizing composition is E. coli, Staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa), Salmonella (S. typhimurium), Flexneriri. It provides a sterilizing composition comprising a bismuth leaf extract characterized by at least one selected from the group consisting of S. flexneri and K. pneumoniae.
대한민국약전 일반시험법 중 미생물한도시험법 또는 식약처에서 고시(제2019-71호)한 살균 시험법에 따르면 일반적으로 살균력 시험에서 표준 균주로 대장균(Escherichia coli ATCC 10536 또는 Escherichia coli ATCC 11229), 황색포도상구균(Staphylococcus aureus ATCC 6538)을 사용하고, 상기 표준균주 외에 세레우스균(Bacillus cereus ATCC 21772), 장염비브리오균(Vibrio parahaemolyticus ATCC 27969), 살모넬라균(Salmonella typhimurium ATCC 13311), 리스테리아균 (Listeria monocytogenes ATCC 19111(또는 Listeria monocytogenes ATCC 19115)) 같은 시험균주를 선택하여 추가할 수 있고 생균수 감소율이 99.999% 이상일 때 적합한 것으로 본다고 개시되어 있다.According to the microbial limit test method among general test methods of the Korean Pharmacopoeia or the sterilization test method notified by the Ministry of Food and Drug Safety (No. 2019-71), E. coli ( Escherichia coli ATCC 10536 or Escherichia coli ATCC 11229), yellow Staphylococcus aureus ATCC 6538 is used, and in addition to the standard strain, Cereus bacterium (Bacillus cereus ATCC 21772), Vibrio parahaemolyticus ATCC 27969), Salmonella typhimurium ATCC 13311), Listeria monocytogenes A test strain such as ATCC 19111 (or Listeria monocytogenes ATCC 19115) can be selected and added, and it is disclosed that it is considered suitable when the viable cell number reduction rate is 99.999% or more.
본 발명의 살균용 조성물을 사용한 항균 시험 시, 식약처 고시 시험균주 이외에도 녹농균(P.aeruginosa) 플렉스네리이질균 (S.flexneri), 폐렴간균(K.pneumoniae)에 대한 99.999% 이상의 살균능을 알아볼 수 있었다. 각 시험 균주에 대한 살균 효과는 소독제의 조성과 항균 활성 성분에 따라 달라질 수 있다는 점에서, 하기 균주에 대한 살균능은 본 발명의 비자나무 잎 추출물을 포함하는 살균용 조성물만의 특유한 효과에 해당한다.In the antibacterial test using the sterilizing composition of the present invention, in addition to the test strains notified by the Ministry of Food and Drug Safety, it is possible to find out the sterilization ability of 99.999% or more against P. aeruginosa, S. flexneri, and K. pneumoniae. there was. In that the sterilization effect for each test strain may vary depending on the composition of the disinfectant and the antibacterial active ingredient, the sterilization ability for the following strains corresponds to the unique effect of the sterilization composition containing the extract of the leaves of the present invention. .
녹농균은 호기성 그람 음성세균으로 간균에 속하며 아포(spore)를 형성하지 않는다. 이 균은 선천적으로 항생제에 대한 저항성을 가지고 있기 때문에 의학적 연구로 많이 사용된다. 또한 기회감염성을 띄고 있어 건강한 사람에겐 큰 해를 끼치지 않지만 낭포성 섬유증(cystic fibrosis) 환자나 면역력이 저하된 사람에게 매우 심각한 감염을 일으킬 수 있다. 녹농균은 최저 영양 조건에서도 성장이 가능하기 때문에 성장 범위가 매우 넓다. 특히 병원 내의 습한 환경, 기구들과 심지어 소독용 용액 등 도처에 존재하고 있다. Pseudomonas aeruginosa is an aerobic gram-negative bacteria, belongs to bacillus, and does not form spores. Because this fungus is inherently resistant to antibiotics, it is widely used in medical research. It is also opportunistic, so it does not cause great harm to healthy people, but it can cause very serious infections in people with cystic fibrosis or people with reduced immunity. Pseudomonas aeruginosa can grow even under the lowest nutrient conditions, so its growth range is very wide. Especially in humid environments in hospitals, instruments and even disinfectant solutions are everywhere.
세균성이질균(이하 시겔라) 속에는 4개의 종이 포함되며, 플렉스네리이질균은 플렉스너이질균, B군이질균, 시겔라.B군이질균이라고도 불리운다. 사람의 급성 설사병의 가장 흔한 원인균의 하나이다. 시겔라는 그람 음성, 통성혐기성균으로 편모(flagella)를 가지지 않아 비운동성이다. 아직까지 백신이 개발되지 않았으며 각 종은 물론 종 내의 혈청형간에도 교차면역이 발생하지 않기 때문에 백신개발에 어려움이 있다. 시겔라는 분변-구강 경로를 통해 전파되는데 시겔라가 산성 환경에 내성을 가져서 위에서 살아 남아 장까지 전달될 수 있기 때문에 10~100개의 세균을 섭취하는 것으로도 발병할 수 있을 정도로 전염성이 강하다. Four species are included in the bacterial Shigella (hereinafter referred to as Shigella), and the Flexneri Shigella is also called Flexner Shigella, Group B Shigella, Shigella, and Group B Shigella. It is one of the most common causative agents of acute diarrhea in humans. Shigella is a Gram-negative, painless anaerobic bacteria that does not have flagella and is non-motile. Vaccines have not been developed yet, and cross-immunity does not occur between serotypes within the species as well as each species, making it difficult to develop a vaccine. Shigella is transmitted through the fecal-oral route, and because Shigella is resistant to an acidic environment and can be passed on to the intestine by surviving in the stomach, it is highly contagious enough to cause disease even by ingesting 10 to 100 bacteria.
폐렴간균(Klebsiella pneumonia)는 막대모양의 그람음성균이며, 조건부 혐기성, oxidase 양성의 특성을 가진다. 이 세균은 장내세균군(enteric bacteria)에 속하고 피부와 구강에도 존재하는 공생균이다. 면역이 저하된 환자에게는 패혈증(septicemia), 폐렴(pneumonia), 비뇨기감염, 연부조직감염과 같은 기회감염(opportunistic infection)을 일으키는 세균으로 간주되고 있다. 특히 이 세균은 광범위 베타락탐 분해효소[extended-spectrum β-lactamase (ESBL)]를 축적하고, 다른 세균으로 관련유전자를 이동시키기도 한다. 이런 ESBL를 생산하는 K. pneumoniae의 경우에는 다양한 항생제에도 내성을 가지게 되기 때문에, 이에 의한 감염증의 치료는 매우 어렵게 된다. Klebsiella pneumonia is a rod-shaped gram-negative bacterium, and is conditionally anaerobic and oxidase-positive. This bacterium belongs to enteric bacteria and is a symbiotic bacteria present in the skin and oral cavity. It is considered as a bacteria that causes opportunistic infections such as sepsis, pneumonia, urinary tract infection, and soft tissue infection in patients with reduced immunity. In particular, this bacterium accumulates extensive beta-lactam-degrading enzyme [extended-spectrum β-lactamase (ESBL)] and also transfers related genes to other bacteria. In the case of K. pneumoniae , which produces these ESBLs, it becomes resistant to various antibiotics, making it very difficult to treat infectious diseases.
낮은 수준의 소독으로 사멸되지 않는 녹농균이나, 산성 환경에 내성을 가지는 이질균, 및 다양한 항생제에 내성을 가지는 폐렴간균등은 종래에 중간 수준 이상의 복잡한 소독 방법으로만 사멸이 가능하였으며, 간단한 방법으로는 사멸시키기 어려운 균주에 해당하였다. 본 발명에서 손 소독제를 사용하는 행위만으로 상기 균주를 99.999% 사멸시킬 수 있다는 것은 종래 존재하지 않았던 본 발명만의 새로운 발견에 해당한다. Pseudomonas aeruginosa, which is not killed by a low level of disinfection, Shigella aeruginosa, which is resistant to an acidic environment, and pneumonia bacilli, which are resistant to various antibiotics, can be killed only by a complex disinfection method of medium or higher levels in the past. Corresponds to the strain that is difficult to do. In the present invention, the fact that 99.999% of the strain can be killed only by using a hand sanitizer corresponds to a novel discovery of the present invention that did not exist before.
본 발명의 일 구현예에 있어서 상기 살균용 조성물을 인체 피부에 직접 사용할 수 있는 것을 특징으로 하는 비자나무 잎 추출물을 제공한다.In one embodiment of the present invention, it provides a birch leaf extract, characterized in that the sterilizing composition can be used directly on human skin.
상기 살균용 조성물은 세포독성이 존재하지 않고 인체 피부에 대한 안전성이 확인되어 피부에 자극을 주기 않으므로, 상기 살균용 조성물을 인체 피부에 직접 사용 가능하다. Since the sterilizing composition does not have cytotoxicity and does not irritate the skin because it has been confirmed that it is safe for human skin, the sterilizing composition can be used directly on the human skin.
본 발명에 따른 화장료 조성물은 국소적용에 적합한 모든 제형으로 제공될 수 있다. 예를 들면, 용액, 에멀젼, 현탁액, 고체, 겔, 분말, 페이스트, 폼 또는 에어로졸 조성물의 제형으로 제공될 수 있으며, 이러한 제형의 조성물은 당해 분야의 통상적인 방법에 따라 제조될 수 있다.The cosmetic composition according to the present invention may be provided in any formulation suitable for topical application. For example, it may be provided in the form of a solution, emulsion, suspension, solid, gel, powder, paste, foam or aerosol composition, and the composition of such a formulation may be prepared according to conventional methods in the art.
본 발명에 따른 화장료 조성물은 보습제, 에몰리언트제, 계면 활성제, 자외선 흡수제, 방부제, 살균제, 산화 방지제, pH 조절제, 유기 및 무기 안료, 향료, 냉감제 또는 제한제 등을 더 포함할 수 있다. The cosmetic composition according to the present invention may further include a moisturizing agent, an emollient agent, a surfactant, a UV absorber, a preservative, a fungicide, an antioxidant, a pH adjuster, an organic and inorganic pigment, a fragrance, a cooling agent or a limiting agent.
본 발명에 따른 비자나무 잎 추출물은 높은 카테킨 및 탄닌산을 포함하는 천연 물질로서, 바이러스 종에 따라 99%에 이르는 항바이러스 활성을 가지고 있어 항바이러스용 조성물로 활용될 수 있다. As a natural substance containing high catechin and tannic acid according to the present invention, the extract of the leaves of the birch tree according to the present invention has an antiviral activity of up to 99% depending on the virus species, and thus can be used as an antiviral composition.
본 발명에 따른 비자나무 잎 추출물을 포함하는 살균용 조성물은 기존 에탄올 소독제의 단점을 보완하여, 대한민국약전 일반시험법 및 식약처 고시에 따른 세균뿐만 아니라, 다양한 감염성 균에 99.999% 이상의 안정적이고 높은 살균능을 나타낸다. The composition for sterilization comprising the extract of birch leaves according to the present invention complements the shortcomings of the existing ethanol disinfectant, and provides a stable and high sterilization of 99.999% or more against various infectious bacteria, as well as bacteria according to the Korean Pharmacopoeia General Test Method and KFDA notice. Show ability.
본 발명에 따른 살균용 조성물은 피부에 직접 적용하여도 부작용 내지 독성의 위험에 대한 우려가 없다. Even if the composition for sterilization according to the present invention is applied directly to the skin, there is no concern about the risk of side effects or toxicity.
이하, 본 발명을 실시예 등에 의거하여 구체적으로 설명하고자 하는 바, 다음 실시예 등에 의하여 본 발명이 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail based on examples and the like, but the present invention is not limited by the following examples.
실시예 1. 비자나무 잎 추출Example 1. Extract of birch leaves
제주도, 장성 또는 고흥 등 남부지방에서 채취한 비자나무 잎 1kg을 파쇄하여 100% 에탄올을 첨가하여 혼합한 후 가열하여 70℃에서 3시간 추출하였다. 1 kg of birch leaves collected from southern regions such as Jeju Island, Jangseong or Goheung were crushed, mixed with 100% ethanol, heated, and extracted for 3 hours at 70°C.
실시예 2. 비자나무 잎 추출물을 포함하는 살균용 조성물의 제조Example 2. Preparation of a composition for sterilization containing the extract of birch leaves
상기 살균용 조성물 총 부피 1L 기준으로, 에탄올 0.6L, 정제수 0.25L, 글리세린 0.1L, 비자나무 잎 추출물 0.05L를 혼합한다. Based on the total volume of the sterilizing composition 1L, 0.6L of ethanol, 0.25L of purified water, 0.1L of glycerin, and 0.05L of birch leaf extract are mixed.
<실험예 1> 본 발명 비자나무 잎 추출물의 성분<Experimental Example 1> Ingredients of the extract of the leaf extract of the present invention
실시예 1에서 제조한 비자나무 잎 추출물의 성분을 분석하였다.The components of the extract of the leaf extract prepared in Example 1 were analyzed.
하기 표 1의 검랑범위는 1~1000 ng/ml (카테킨에 대하여는 2~2000 ng/ml)이며 시료 희석 배수를 환산하여 얻은 결과는 아래와 같다.The gumrang range of Table 1 below is 1 to 1000 ng/ml (2 to 2000 ng/ml for catechin), and the results obtained by converting the sample dilution factor are as follows.
* N/A: Not detected* N/A: Not detected
상기 표 1, 표 2에서 알 수 있는 바와 같이, 본 발명의 비자 나무 잎 추출물은 16300ng/ml의 카테킨을 포함하고 있고, 86400ng/mL 이상의 탄닌산을 포함한다. 본 발명의 비자나무 잎 추출물의 높은 카테킨과 탄닌 함량으로 인해 비자나무 잎 추출물을 포함하는 조성물은 뛰어난 살균 및 항바이러스능을 나타낸다. As can be seen in Tables 1 and 2, the extract of the leaves of the birch tree of the present invention contains 16300 ng/ml of catechin, and contains more than 86400 ng/mL of tannic acid. Due to the high catechin and tannin content of the extract of the extract of the leaves of the extract of the present invention, the composition including the extract of the extract of the leaf of the extract of the present invention exhibits excellent bactericidal and antiviral activity.
<실험예 2> 비자나무 잎 추출물을 포함하는 살균용 조성물에 대한 균주별 항균 효과 실험<Experimental Example 2> Antimicrobial effect test for each strain on a sterilizing composition containing a birch leaf extract
본 발명인 실시예 2의 비자나무 잎 추출물을 포함하는 살균용 조성물의 항균스펙트럼을 조사하기 위해,In order to investigate the antimicrobial spectrum of the composition for sterilization comprising the extract of the leaves of the present invention in Example 2,
항균실험 방법은 ASTM E2315-16을 이용하였고, 시험 조건은 원액 농도에서 반응온도 (22±2)℃에서 사용하였으며, 반응시간은 5분이었다. The antibacterial test method was ASTM E2315-16, and the test conditions were at the reaction temperature (22±2)°C at the concentration of the stock solution, and the reaction time was 5 minutes.
실험 균주로는 As an experimental strain
Escherichia coli (E. coli) ATCC 10536, Escherichia coli (E. coli) ATCC 10536,
Staphylococcus aureus (S.aureus) ATCC 6538, Staphylococcus aureus (S.aureus) ATCC 6538,
Pseudomonas aeroginosa (P. aeroginosa) ATCC 15522, Pseudomonas aeroginosa (P. aeroginosa) ATCC 15522,
Salmonella typhimurium (S. typhimurium) ATCC 13311, Salmonella typhimurium (S. typhimurium) ATCC 13311,
Shigella flexneri (S. flexneri) ATCC 12022, 및Shigella flexneri (S. flexneri) ATCC 12022, and
Klebsiella pneumoniae (K. pneumoniae) ATCC 4352를 사용하였다.Klebsiella pneumoniae (K. pneumoniae) ATCC 4352 was used.
살균 실험 결과를 아래의 표 3에 나타내었다.The results of the sterilization experiment are shown in Table 3 below.
Log reduction(LR) = mean log(microbial population) - mean log(surviving test population)Log reduction(LR) = mean log(microbial population)-mean log(surviving test population)
log reduction 1 이상: 90% 이상log reduction 1 or more: 90% or more
log reduction 2 이상: 99% 이상log reduction 2 or more: 99% or more
log reduction 3 이상: 99.9% 이상log reduction 3 or more: 99.9% or more
log reduction 4 이상: 99.99% 이상log reduction 4 or more: 99.99% or more
log reduction 5 이상: 99.999% 이상log reduction 5 or more: 99.999% or more
상기 표 3에 나타나 있듯이, 본 발명의 비자나무 잎 추출물을 포함하는 손 소독제는 그람양성균인 황색포도상구균(S.aureus)과 그람음성균인 대장균(E.coli), 녹농균(P. aeruginosa), 살모넬라균(S. typhimurium), 플렉스네리이질균(S. flexneri), 페렴간균(K. pneumonia) 모두에 대해 99.999% 이상의 높은 항균 활성을 나타내며 이는 식약처에서 고시한 소독제의 기준을 만족하는 것을 뛰어넘어 낮은 수준의 소독으로는 살균되지 않는 균주에도 뛰어난 항균능을 보임을 알 수 있다.As shown in Table 3, the hand sanitizer containing the extract of the leaf extract of the present invention is S. aureus, which is a Gram-positive bacteria, and E. coli, which is a gram-negative bacteria, P. aeruginosa, and Salmonella It exhibits a high antibacterial activity of 99.999% or more against all of S. typhimurium, S. flexneri, and K. pneumonia, which exceeds that of satisfying the standards for disinfectants notified by the Ministry of Food and Drug Safety, and is low. It can be seen that it shows excellent antibacterial activity even in strains that are not sterilized by level of disinfection.
<실험예 3> 비자나무 잎 추출물을 포함하는 조성물에 대한 항바이러스 효과 실험<Experimental Example 3> Antiviral effect test on a composition containing a birch leaf extract
본 발명인 실시예 2의 비자나무 잎 추출물의 항바이러스 스펙트럼을 조사하기 위해 ASTM E1052-20 방법을 사용하였고, 시험 조건은 100% 에틸 알코올에 본 발명의 비자나무 잎 추출액을 0.1%(v/v) 로 희석한 희석액을 반응온도 (22±2)℃에서 사용하였으며, 반응시간은 5분이었다. ASTM E1052-20 method was used to investigate the antiviral spectrum of the extract of the extract of the leaves of the present invention in Example 2, and the test conditions were 0.1% (v/v) of the extract of the extract of the leaf of the present invention in 100% ethyl alcohol. The diluted solution diluted with was used at the reaction temperature (22±2)℃, and the reaction time was 5 minutes.
바이러스로는 Human respiratory syncytial virus, Strain: Long, ATCC VR-26Viruses include Human respiratory syncytial virus, Strain: Long, ATCC VR-26
Rotavirus A, Strain: Wa (TC adapted), ATCC VR-2018 및Rotavirus A, Strain: Wa (TC adapted), ATCC VR-2018 and
Human influenza A(H1N1), Strain: KUMC-76, KBPV-VR-76을 사용하였다.Human influenza A (H1N1), Strain: KUMC-76, KBPV-VR-76 were used.
숙주세포로는 Hep-2, KCLB 10023,Host cells include Hep-2, KCLB 10023,
CV-1, KCLB 10070 및CV-1, KCLB 10070 and
MDCK (NBL-2), ATCC CCL-34 를 사용하였다.MDCK (NBL-2) and ATCC CCL-34 were used.
살균 실험 결과를 아래의 표 4에 나타내었다.The results of the sterilization experiment are shown in Table 4 below.
(Human respiratory syncytial virus) Antiviral test
(Human respiratory syncytial virus)
(Rotavirus A)Antiviral test
(Rotavirus A)
[Human influenza A(H1N1)]Antiviral test
[Human influenza A(H1N1)]
Log reduction(LR) = LU(바이러스 대조군의 역가(untreated))-LT(바이러스 시험군의 역가(treated))Log reduction (LR) = LU (untreated viral control group)-LT (treated viral test group)
log reduction 1 이상: 90% 이상log reduction 1 or more: 90% or more
log reduction 2 이상: 99% 이상log reduction 2 or more: 99% or more
log reduction 3 이상: 99.9% 이상log reduction 3 or more: 99.9% or more
log reduction 4 이상: 99.99% 이상log reduction 4 or more: 99.99% or more
log reduction 5 이상: 99.999% 이상log reduction 5 or more: 99.999% or more
상기 표 4에 나타나 있듯이, 본 발명의 비자나무 잎 추출물은 호흡기 세포 융합 바이러스(Human respiratory syncytial virus)에는 99.9% 이상의 바이러스 증식 수준 감소율을, 장염 바이러스 A(Rotavirus A)에는 90% 이상의 바이러스 증식 수준 감소율을, 인간 인플루엔자 A(Human influenza A, H1N1)에는 99% 이상의 바이러스 증식 수준 감소율을 보였다. 이는 본원 발명의 비자나무 잎 추출물이 전염성 바이러스 감소에 높은 항바이러스 활성을 가짐을 나타낸다.As shown in Table 4, the leaf extract of the present invention has a reduction rate of 99.9% or more of virus proliferation level in the human respiratory syncytial virus, and 90% or more of virus proliferation level reduction in enteritis virus A (Rotavirus A). In human influenza A (H1N1), the virus proliferation level decreased by more than 99%. This indicates that the extract of the leaf extract of the present invention has high antiviral activity in reducing infectious viruses.
이상 본 발명의 바람직한 실시예를 설명하였지만, 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해되어야 하고, 본 발명의 범위는 상세한 설명보다는 후술하는 특허청구범위에 의하여 나타내어지며, 특허청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.Although preferred embodiments of the present invention have been described above, the embodiments described above are illustrative in all respects and should be understood as non-limiting, and the scope of the present invention is indicated by the claims to be described later rather than the detailed description. , All changes or modified forms derived from the meaning and scope of the claims and their equivalent concepts should be interpreted as being included in the scope of the present invention.
Claims (7)
상기 비자나무 잎 추출물은 프로토카테츄산 에틸 에스테르, 4-히드록시 벤조산, 링산, 쿠마르산, 루틴, 페룰산, 나린제닌, 레스베라톨, 니코틴산, 갈릭산, 프로토카테츄산, 카테킨, 탄닌산으로 이루어진 군에서 선택되는 하나 이상을 포함하는 것을 특징으로 하는 항바이러스용 약학 조성물.A pharmaceutical composition for antiviral comprising extracts of leaves of birch leaves,
The group consisting of protocatechuic acid ethyl ester, 4-hydroxybenzoic acid, ringic acid, comaric acid, rutin, ferulic acid, naringenin, resveratol, nicotinic acid, gallic acid, protocatechuic acid, catechin, and tannic acid. Antiviral pharmaceutical composition comprising at least one selected from.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200105977A KR102252009B1 (en) | 2020-08-24 | 2020-08-24 | Antiviral or antibacterial composition containing extracts of Torreya nucifera leaf |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200105977A KR102252009B1 (en) | 2020-08-24 | 2020-08-24 | Antiviral or antibacterial composition containing extracts of Torreya nucifera leaf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102252009B1 true KR102252009B1 (en) | 2021-05-18 |
Family
ID=76158543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200105977A Active KR102252009B1 (en) | 2020-08-24 | 2020-08-24 | Antiviral or antibacterial composition containing extracts of Torreya nucifera leaf |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102252009B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024079468A1 (en) * | 2022-10-12 | 2024-04-18 | Chariot Innovations Ltd | Compounds for use as medicaments |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080109345A (en) * | 2007-06-13 | 2008-12-17 | 재단법인 제주하이테크산업진흥원 | Non-oil Extract for Antibacterial |
| KR20180006551A (en) | 2016-07-08 | 2018-01-18 | 김혜영 | Antimircrobial Composition Including a Extract Derived from Torreya nucifera |
-
2020
- 2020-08-24 KR KR1020200105977A patent/KR102252009B1/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080109345A (en) * | 2007-06-13 | 2008-12-17 | 재단법인 제주하이테크산업진흥원 | Non-oil Extract for Antibacterial |
| KR20180006551A (en) | 2016-07-08 | 2018-01-18 | 김혜영 | Antimircrobial Composition Including a Extract Derived from Torreya nucifera |
Non-Patent Citations (2)
| Title |
|---|
| "비자나무 잎 추출물로 항바이러스 손소독제 제조", 연합뉴스(2020.04.05.) 1부.* * |
| 목재공학(Journal of the Korean Wood Science and Technology), 29권4호(2001), pp.53-59(2001.12.31.) 1부.* * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024079468A1 (en) * | 2022-10-12 | 2024-04-18 | Chariot Innovations Ltd | Compounds for use as medicaments |
| GB2623499A (en) * | 2022-10-12 | 2024-04-24 | Chariot Innovations Ltd | Compounds for use as medicaments |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5092145B2 (en) | Anti-norovirus agent and composition containing the same | |
| JP5421901B2 (en) | Antiviral agent and antiviral composition against non-enveloped viruses of the genus Enterovirus | |
| JP5670201B2 (en) | Antiviral agent and antiviral composition against envelope virus belonging to influenza A virus genus | |
| Sahu et al. | Urinary tract infection and its management | |
| KR102149973B1 (en) | Antimicrobial and Antifungal Composition Comprising Eugenol and Gallic Acid as Active Ingredient | |
| KR20160079473A (en) | Preparation method of cleaning or disinfecting composition having antiviral activity by containing green tea extract as active component | |
| CN104738033A (en) | Preservative composition derived from plants | |
| US20070065527A1 (en) | Activated citrus peel extract | |
| KR102171948B1 (en) | Antimicrobial and Antifungal Composition Composition Comprising Mixture of Herb Essential Oil as Active Ingredient | |
| KR102154252B1 (en) | Composition for Antimicrobial and Antifungal Comprising Baicalein and Wogonin as Active Ingredient | |
| KR101349101B1 (en) | Natural germicide composition and methods for manufacturing a natural germicide | |
| KR102252009B1 (en) | Antiviral or antibacterial composition containing extracts of Torreya nucifera leaf | |
| CN111493097A (en) | Collective disinfectant for inhibiting viruses and pathogenic bacteria and preparation method thereof | |
| KR101121615B1 (en) | Antibacterial Detergent Composition | |
| KR20160079459A (en) | Cleaning or disinfecting composition having antiviral activity by containing green tea extract as active component | |
| CN119698238A (en) | Biocide composition | |
| KR20090046387A (en) | Cosmetic composition having antiseptic activity as extract of golden, eoseongcho, mugwort, and citron | |
| KR20160084904A (en) | Composition for sanitation promotion of oral cavity comprising natural medicinal ingredient extract as effective component | |
| Chandravanshi et al. | Formulation of herbal hand sanitizer from Indian herbs | |
| KR20210044762A (en) | Anti-microbial composition comprising pinus koraiensis sieb extract | |
| KR102312393B1 (en) | Composition for disinfection and sterilization comprising natural extracts | |
| Yeh et al. | Antibacterial and antibiofilm effects of Camellia oleifera seed dreg extract and its application in cosmetics | |
| Al-Dabbagh et al. | Comparison of antimicrobial activity of four herbal extracts against streptococcus mutans, isolated from dental diseases in vitro | |
| Parviz et al. | Tea Tree (Melaleuca alternifolia (Maiden & Betche) Cheel) Oil an important medicinal essential oil | |
| KR102074558B1 (en) | ANTIBACTERAL COMPOSITION AGAINST PATHOGENIC BACTERIA COMPRISING EXTRACT OF Forsythia suspensa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20200824 |
|
| PA0201 | Request for examination | ||
| PA0302 | Request for accelerated examination |
Patent event date: 20200825 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination Patent event date: 20200824 Patent event code: PA03021R01I Comment text: Patent Application |
|
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20201203 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20210326 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20210510 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20210511 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20240111 Start annual number: 4 End annual number: 4 |